What Purdue Pharma may have known about an OxyContin ring in L.A.

A Los Angeles Times investigation alleges Purdue Pharma, the maker of OxyContin, continued supplying clinics and pharmacies it suspected of trafficking the highly addictive drug and never alerted law enforcement.

In one case, it continued supplying a single doctor clinic that, in just four months, prescribed 73,000 pills—which have a street value of more than $6 million.

To read more about the investigation, and why Purdue feels it was justified in not alerting federal agents, click on the link below:  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.